Skip to content
Screener

Precigen PGEN Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$2.63B-43.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
Gilead Sciences logo
Gilead SciencesGILD
-$4.24B-23.7%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$21.12M+51.0%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$411.17M+66,004%
Regenxbio logo
RegenxbioRGNX
$17.57M-87.4%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$2.47B+358%
Enterprise value$2.56B+382%
P/S93.2×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Precigen’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356090-26-000017
(Amounts in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Payment of issuance cost related to 2024 public offering of shares(355)
Payments to taxing authorities in connection with shares directly withheld from employees(146)(474)
Proceeds from stock option exercises255150
Net cash provided by (used in) financing activities109(679)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash(3)2
Net decrease in cash, cash equivalents, and restricted cash(22,754)(23,459)
Cash, cash equivalents, and restricted cash
Beginning of period30,23429,517

Item 1. Condensed Consolidated Financial Statements

FAQ

What is Precigen's financing cash flow?
Precigen (PGEN) reported financing cash flow of $109K in Q1 2026.
How has Precigen's financing cash flow changed year-over-year?
Precigen's financing cash flow increased by 116.1% year-over-year, from -$679K to $109K.
What is the long-term trend for Precigen's financing cash flow?
Over 3 years (2021 to 2025), Precigen's financing cash flow has grown at a -9.3% compound annual growth rate (CAGR), from $121.3M to $90.56M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Precigen's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude